Amoxicillin Trihydrate

證據等級: L5

預測適應症: 0 個

Amoxicillin Trihydrate: Repurposing Evaluation — No Prediction Currently Available

One-Sentence Summary

Amoxicillin Trihydrate is a broad-spectrum beta-lactam antibiotic widely used to treat bacterial infections. The TxGNN model did not generate a repurposing prediction for this drug in the current analysis run, as two critical data gaps — regulatory safety information and mechanism of action — remain unresolved. No evidence-based evaluation of a new indication can be completed at this stage.

Quick Overview

Item	Content
Original Indication	Bacterial infections (general knowledge; regulatory indication text not retrieved)
Predicted New Indication	— (No prediction generated)
TxGNN Prediction Score	—
Evidence Level	N/A
Malaysia Market Status	✓ Marketed
Number of Registrations	81
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction has been generated by TxGNN for this drug in the current pipeline run, so a mechanistic rationale for a specific new indication cannot be provided.

From general pharmacological knowledge, Amoxicillin Trihydrate is an aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by binding irreversibly to penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking and ultimately causing bacterial cell lysis. It is active against a broad spectrum of Gram-positive organisms and select Gram-negative bacteria. Its established clinical uses include respiratory tract infections, urinary tract infections, otitis media, and skin and soft tissue infections.

Mechanism of action data was formally flagged as a High-severity data gap (DG002), and regulatory indication text from Malaysia NPRA was not retrieved in this run. Until these gaps are resolved and a TxGNN prediction is produced, applicability to any repurposing target cannot be assessed.

Clinical Trial Evidence

Currently no related clinical trials registered for repurposing.

Literature Evidence

Currently no related literature available for repurposing.

Malaysia Market Information

81 active registrations are recorded in the Malaysia NPRA database. However, individual product details — including authorization numbers, product names, dosage forms, and approved indication text — were not retrieved in this analysis run. The table below cannot be populated until a full NPRA product-level query is completed.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	(Data not retrieved; 81 registrations confirmed at aggregate level)

Safety Considerations

Please refer to the package insert for safety information.

Note: Two data gaps directly block safety evaluation:

DG001 (Blocking): Malaysia NPRA package insert warnings and contraindications have not been retrieved. This prevents completion of the standard safety screening step (S1).

No drug–drug interactions were identified in the current query (DDI query status: not_found), but this result should be treated as inconclusive until DG001 is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN has not yet generated a repurposing candidate for Amoxicillin Trihydrate, and a Blocking-severity data gap (DG001) prevents the mandatory safety pre-screen from being completed. Proceeding without resolving these gaps would produce an incomplete and potentially misleading assessment.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve Malaysia NPRA package insert warnings and contraindications by downloading and parsing the official product monograph PDF from the NPRA website; this must be completed before any safety evaluation can begin
[DG002 — High] Query the DrugBank API using the INN “amoxicillin” to obtain confirmed MOA, pharmacodynamics, and toxicity data
Re-run TxGNN prediction pipeline after confirming that Amoxicillin Trihydrate’s DrugBank ID is correctly resolved and linked to the knowledge graph; the current drugbank_id: null likely explains why no prediction was generated
Retrieve full NPRA product-level data for all 81 registered products (authorization numbers, product names, dosage forms, approved indications) to complete the Malaysia Market Information section
Once a prediction is generated, re-evaluate evidence level and decision recommendation using the standard L1–L5 framework
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.